Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Gastroesophageal Reflux

Treatments: Drug: Esomeprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00392002

EncomPASS

D9612L00096

Details and patient eligibility

About

To characterize the burden of disease in GERD patients of prescription therapy'

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent, 18 years or older, diagnosis of GERD

Exclusion criteria

• Peptic ulcer disease, upper gastrointestinal surgery, malignancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)